CymaBay Therapeutics Inc (NASDAQ:CBAY) Director Kurt Von Emster sold 18,831 shares of CymaBay Therapeutics stock in a transaction on Monday, February 5th. The shares were sold at an average price of $12.14, for a total transaction of $228,608.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Kurt Von Emster also recently made the following trade(s):

  • On Friday, February 2nd, Kurt Von Emster sold 90,098 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.15, for a total transaction of $1,094,690.70.
  • On Wednesday, January 31st, Kurt Von Emster sold 97,639 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.22, for a total transaction of $1,193,148.58.
  • On Thursday, January 25th, Kurt Von Emster sold 39,438 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $12.18, for a total transaction of $480,354.84.
  • On Monday, January 22nd, Kurt Von Emster sold 138,253 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.40, for a total transaction of $1,437,831.20.
  • On Friday, January 19th, Kurt Von Emster sold 144,216 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $10.25, for a total transaction of $1,478,214.00.
  • On Friday, January 5th, Kurt Von Emster sold 4,300 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $10.21, for a total transaction of $43,903.00.
  • On Friday, December 22nd, Kurt Von Emster sold 173,192 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.41, for a total transaction of $1,629,736.72.
  • On Friday, November 10th, Kurt Von Emster sold 50,048 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.26, for a total transaction of $463,444.48.

CymaBay Therapeutics Inc (NASDAQ CBAY) traded up $0.71 during trading on Wednesday, hitting $12.50. 1,159,179 shares of the company traded hands, compared to its average volume of 819,691. CymaBay Therapeutics Inc has a 1-year low of $1.92 and a 1-year high of $12.77. The company has a quick ratio of 7.39, a current ratio of 7.39 and a debt-to-equity ratio of 0.04. The stock has a market cap of $548.30, a price-to-earnings ratio of -12.38 and a beta of 2.04.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). During the same period last year, the firm posted ($0.25) EPS. research analysts forecast that CymaBay Therapeutics Inc will post -0.87 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC purchased a new stake in shares of CymaBay Therapeutics in the 3rd quarter worth about $18,948,000. Vanguard Group Inc. boosted its position in shares of CymaBay Therapeutics by 20.7% in the 2nd quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock worth $5,712,000 after buying an additional 170,126 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of CymaBay Therapeutics in the 3rd quarter worth about $5,159,000. EAM Investors LLC purchased a new stake in shares of CymaBay Therapeutics in the 3rd quarter worth about $4,788,000. Finally, Omega Fund Management LLC boosted its position in shares of CymaBay Therapeutics by 82.9% in the 3rd quarter. Omega Fund Management LLC now owns 551,477 shares of the biopharmaceutical company’s stock worth $4,445,000 after buying an additional 250,000 shares in the last quarter. Institutional investors and hedge funds own 54.70% of the company’s stock.

Several equities research analysts have commented on CBAY shares. Piper Jaffray Companies restated a “buy” rating and set a $12.00 target price on shares of CymaBay Therapeutics in a research report on Friday, October 27th. Oppenheimer set a $15.00 target price on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 30th. Cantor Fitzgerald restated a “buy” rating and set a $16.00 target price on shares of CymaBay Therapeutics in a research report on Wednesday, November 8th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Finally, Leerink Swann restated a “buy” rating and set a $16.00 target price on shares of CymaBay Therapeutics in a research report on Tuesday, November 28th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $16.56.

TRADEMARK VIOLATION WARNING: “CymaBay Therapeutics Inc (CBAY) Director Kurt Von Emster Sells 18,831 Shares” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/02/08/cymabay-therapeutics-inc-cbay-director-kurt-von-emster-sells-18831-shares.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Insider Buying and Selling by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.